Versorgungsforschung in onkologischen Schwerpunktpraxen in Deutschland

Weide, Rudolf

doi:10.1007/s00761-017-0292-9

Cited by 2 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This bias can be explained by variably strict study exclusion criteria and by focusing on patient populations that require treatment for their underlying hematological diseases. In addition many studies mostly include younger patients which may underestimate the risk of infections in older patients, if the obtained data are used to generalize the risk of infections [ 28 , 29 ].…”

Section: Introductionmentioning

confidence: 99%

Patients with indolent lymphomas are at high risk of infections: experience from a German outpatient clinic

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background Patients with indolent B-cell non-Hodgkin lymphomas (B-NHLs) have an increased risk of infections which is caused by pathomechanisms of the diseases itself but also as a result of anti-tumor therapy. Especially the effects of anti-CD20 antibodies are well understood as these lead to decreased antibody production. Most studies regarding immunodeficiency in B-NHLs were conducted with multiple myeloma and chronic lymphocytic leukemia patients. As these studies not always represent the general population we collected and analyzed real world data from patients with indolent lymphomas and a control group (CG). Results Patients with B-NHLs undergoing therapy or who were regularly monitored in a watch and wait approach had, over the time of one year, an increased rate of infections compared to the CG of 145 healthy volunteers (mean: 11.66 vs. 7.13 infections per 1000 days). Consistent with this finding B-NHL patients received more antibiotic treatment (mean: 11.17 vs. 6.27 days) and were more often hospitalized than persons from the CG (mean: 5.19 vs. 0.99 days per 1000 days). Lymphoma patients without immunodeficiency had a lower infection rate than patients with non-symptomatic and symptomatic immunodeficiency (mean: 10.91 vs. 12.07 and 12.36 per 1000 days). The number of infections differed statistically significant for the subgroups and CG (7.13 per 1000 days). Patients with symptomatic immunodeficiency were mostly treated with regular immunoglobulin substitutions and infection rates were comparable to those of patients with asymptomatic immunodeficiency. Conclusions Our data suggest the use of an approach with regular immune monitoring including the measurement of immunoglobulin levels and regular appointments for clinical assessment of all indolent lymphoma patients in order to identify patients with increased risk of infections. It also raises the question if patients with immunodeficiency should be treated more often with regular immunoglobulin substitution, but so far more studies are necessary to answer this question.

show abstract

Section: Introductionmentioning

confidence: 99%

Patients with indolent lymphomas are at high risk of infections: experience from a German outpatient clinic

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

DNVF-Memorandum Versorgungsforschung in der Onkologie

et al. 2020

View full text Add to dashboard Cite

ZusammenfassungVersorgungsforschung in der Onkologie beschäftigt sich mit allen Situationen, in denen Menschen mit Krebs konfrontiert sind. Sie betrachtet die verschiedenen Phasen der Versorgung, also Prävention/Früherkennung, Prähabilitation, Diagnostik, Therapie, Rehabilitation und Palliativversorgung ebenso wie die verschiedenen Akteure, darunter die Betroffenen, die Versorgenden und die Selbsthilfe. Sie befasst sich mit Gesunden (z. B. im Rahmen von Prävention/ Früherkennung), Patientin-nen und Patienten und Krebs-Überlebenden. Aus den Besonderheiten von Krebserkrankungen und den etablierten Versorgungsstrukturen ergeben sich eine Reihe von inhaltlichen Spezifika für die Versorgungsforschung in der Onkologie im Vergleich zur allgemeinen Versorgungsforschung bei im Wesentlichen identischem Methodenkanon. Dieses Memorandum beschreibt den Gegenstand, illustriert die Versorgungsstrukturen und benennt Themenfelder der Versorgungsforschung in der Onkologie. Dieses Memorandum ist eine Ausarbeitung der Fachgruppe Onkologie des Deutschen Netzwerks Versorgungsforschung e. V. und Ergebnis intensiver Diskussionen.

show abstract

Versorgungsforschung in onkologischen Schwerpunktpraxen in Deutschland

Cited by 2 publications

References 22 publications

Patients with indolent lymphomas are at high risk of infections: experience from a German outpatient clinic

Patients with indolent lymphomas are at high risk of infections: experience from a German outpatient clinic

DNVF-Memorandum Versorgungsforschung in der Onkologie

Contact Info

Product

Resources

About